With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds

Kyokai Kenpo Director Toshikazu Yoshimori How should Japan set up its reimbursement system for drugs that are costly but carry benefits for diseases afflicting a large number of people, like Alzheimer’s? Toshikazu Yoshimori, director of the Japan Health Insurance Association...read more